Clinical meaning
Metformin (a biguanide) is the universal first-line pharmacotherapy for type 2 diabetes mellitus per ADA/EASD guidelines, and understanding its mechanisms of action explains both its therapeutic benefits and its unique safety profile. Metformin's primary mechanism is suppression of hepatic glucose production (gluconeogenesis) through activation of AMP-activated protein kinase (AMPK) — a master cellular energy sensor. AMPK activation occurs when metformin inhibits mitochondrial complex I of the electron transport chain, modestly reducing ATP production and increasing the AMP:ATP ratio. Activated AMPK phosphorylates and downregulates key gluconeogenic transcription factors (CREB-regulated transcription coactivator 2, TORC2), reducing expression of gluconeogenic enzymes (phosphoenolpyruvate carboxykinase, glucose-6-phosphatase), thereby decreasing hepatic glucose output — the primary driver of fasting hyperglycemia in type 2 diabetes. Secondary mechanisms include enhanced insulin sensitivity in skeletal muscle (increased GLUT-4 translocation to the cell membrane), reduced intestinal glucose absorption, and favorable effects on the gut microbiome that enhance incretin (GLP-1) secretion. Metformin does not stimulate insulin secretion from pancreatic beta cells, which is why it does not cause hypoglycemia as monotherapy — a critical clinical advantage. Additional benefits beyond glycemic control include weight neutrality or modest weight loss (unlike sulfonylureas and insulin), lipid improvement (reduced LDL and triglycerides), and potential cardiovascular risk reduction demonstrated in the UKPDS trial. The most serious adverse effect is lactic acidosis, which occurs almost exclusively in patients with conditions that impair lactate clearance or increase lactate production — renal impairment (eGFR less than 30 mL/min is an absolute contraindication; dose reduction at eGFR 30-45), hepatic failure, tissue hypoperfusion (decompensated heart failure, sepsis), or hypoxia. Metformin must be held before iodinated contrast procedures (risk of contrast-induced nephropathy impairing metformin clearance) and resumed 48 hours after if renal function remains stable. Chronic use impairs vitamin B12 absorption in the terminal ileum through calcium-dependent membrane action, requiring periodic B12 monitoring. The clinician initiates metformin with dose titration (start 500 mg daily, increase by 500 mg weekly to target 2000 mg/day in divided doses) to minimize GI side effects, monitors renal function and B12 levels, and integrates metformin with lifestyle modification and additional agents based on HbA1c targets, comorbidities (ASCVD, heart failure, CKD), and patient-specific factors.